The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.

A diagnostically useful carrier includes (a) a peptide including the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, and (b) a somatic lysate of Toxocara canis larvae. Further, a kit, use, methods, and compositions that include the diagnostically useful carrier are disclosed.

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

The present invention provides therapeutic molecules for combating sepsis. The invention provides proteins capable of improving survival through immunomodulation in post septicaemia in mammals and oligosaccharides, capable of immuno modulating inflammation in a mammal. The invention provides protein homologs of human HSP70 derived from nematode Setaria digitata and their recombinant forms and oligosaccharides and their role in immunomodulating inflammatory response in a mammal. The invention also provides a composition comprising therapeutic and/or prophylactic proteins and oligosaccharide molecules for immunomodulation in sepsis; and method for treating and/or preventing sepsis, MODS (multiple organ dysfunction syndrome) or septic shock in a mammal.

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.

The invention relates to novel polypeptides which are recognized by anti-Trichinella antibodies. Said polypeptides can be used particularly for detecting anti-Trichinella antibodies and in trichinosis prevention.

The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

The present invention concerns a structurally distinct immunosuppressive mimic of TGF-β that is a potent inducer of murine and human regulatory T cells and provides a therapeutic agent for the treatment of inflammatory disorders. Disclosed herein is a novel parasite TGF-β mimic which fully replicates the biological and functional properties of TGF-β, including binding to mammalian TGF-β receptors and inducing Foxp3.sup.+ Treg in both murine and human CD4.sup.+ T cells. This TGF-β mimic shares no homology to mammalian TGF-β or other members of the TGF-β family, but s distinctly related to the component control protein (CCP) superfamily.

The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants.